S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease
试验速览
- 阶段
- 4 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Fibroscan
研究概览
简要总结
With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy.
详细描述
With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy. Moreover, drugs also have side effects, and there is currently no convenient and effective treatment for people who have non-alcoholic fatty liver disease. The purpose of this trial is that investigating and evaluating the effects on fatty liver, liver fiber, and metabolic indexes after subjects using Shen Pu Yang Gan Wan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 35 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with fatty liver diagnosed by abdominal ultrasound or hepatic fibrometer within half a year's data
- •Subjects with the non-alcoholic fatty liver disease
- •The severity of fatty liver should be at least 3 points by taking an abdominal ultrasound
排除标准
- •Female patients are pregnant or breastfeeding.
- •Patients with viral hepatitis.
- •Long-term drinkers.
- •Those who use slimming products and vitamin E.
研究组 & 干预措施
Shen Pu Yang Gan Wan
Traditional Chinese Medicine
干预措施: Shen Pu Yang Gan Wan (Drug)
Placebo Comparator
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Fibroscan
时间窗: 36 weeks
Measure the changes in the index which is Liver Fibrosis
Change in AST index
时间窗: 36 weeks
Measure the changes in the index which is AST relate to Liver inflammation
Change in ACT index
时间窗: 36 weeks
Measure the changes in the index which is ACT relate to Liver inflammation
Change in HbA1c
时间窗: 36 weeks
Measure the changes in the index which is HbA1c relate to Liver inflammation
次要结局
- Measuring Body Mass Index(36 weeks)